DNA adduct formation in precision-cut rat liver and lung slices exposed to benzo[a]pyrene

被引:66
作者
Harrigan, JA
Vezina, CM
McGarrigle, BP
Ersing, N
Box, HC
Maccubbin, AE
Olson, JR
机构
[1] SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA
[2] Roswell Pk Canc Inst, Dept Mol Pharmacol & Canc Therapeut, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA
关键词
benzo(a)pyrene; DNA adduct; cytochrome P-450; TCDD; tissue slices;
D O I
10.1093/toxsci/kfh030
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Chemical-DNA adducts provide an integrated measure of exposure, absorption, bioactivation, detoxification, and DNA repair following exposure to a genotoxic agent. Benzo[a]pyrene (BaP), a prototypical polycyclic aromatic hydrocarbon (PAH), can be bioactivated by cytochrome P-450s (CYPs) and epoxide hydrolase to genotoxic metabolites which form covalent adducts with DNA. In this study, we utilized precision-cut rat liver and lung slices exposed to BaP to investigate tissue-specific differences in chemical absorption and formation of DNA adducts. To investigate the contribution of bioactivating CYPs (such as CYP1A1 and CYP1B1) on the formation of BaP-DNA adducts, animals were also pretreated in vivo with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) prior to in vitro incubation of tissue slices with BaP. Furthermore, the tissue distribution of BaP and BaP-DNA adduct levels from in vivo studies were compared with those from the in vitro tissue slice experiments. The results indicate a time- and concentration-dependent increase in tissue-associated BaP following exposure of rat liver and lung tissue slices to BaP in vitro, with generally higher levels of BaP retained in lung tissue. Furthermore, rat liver and lung slices metabolized BaP to reactive intermediates that formed covalent adducts with DNA. Total BaP-DNA adducts increased with concentration and incubation time. Adduct levels (fmol adduct/mug DNA) in lung slices were greater than liver at all doses. Liver slices contained one major and two minor adducts, while lung slices contained two major and 3 minor adducts. The tissue-specific qualitative profile of these adducts in tissue slices was similar to that observed from in vivo studies, further validating the use of this model. Pretreatment of animals with TCDD prior to in vitro incubation with BaP potentiated the levels of DNA adduct formation. TCDD pretreatment altered the adduct distribution in lung but not in liver slices. Together, the results suggest that tissue-specific qualitative and quantitative differences in BaP-DNA adducts could contribute to the lung being a target tissue for BaP carcinogenesis. Furthermore, the results validate the use of precision-cut tissue slices incubated in dynamic organ culture as a useful model for the study of chemical-DNA adduct formation.
引用
收藏
页码:307 / 314
页数:8
相关论文
共 36 条
[21]   NUCLEASE-P1-MEDIATED ENHANCEMENT OF SENSITIVITY OF P-32 POSTLABELING TEST FOR STRUCTURALLY DIVERSE DNA ADDUCTS [J].
REDDY, MV ;
RANDERATH, K .
CARCINOGENESIS, 1986, 7 (09) :1543-1551
[22]  
ROSS J, 1990, CANCER RES, V50, P5088
[23]   ACTION BY THE LUNGS ON CIRCULATING XENOBIOTIC AGENTS, WITH A CASE-STUDY OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF BENZO(A)PYRENE DISPOSITION [J].
ROTH, RA ;
VINEGAR, A .
PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :143-155
[24]   Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P4501B1 and purified liver epoxide hydrolase [J].
Shimada, T ;
Gillam, EMJ ;
Oda, Y ;
Tsumura, F ;
Sutter, TR ;
Guengerich, FP ;
Inoue, K .
CHEMICAL RESEARCH IN TOXICOLOGY, 1999, 12 (07) :623-629
[25]  
Shimada T, 1996, CANCER RES, V56, P2979
[26]   Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor [J].
Shimizu, Y ;
Nakatsuru, Y ;
Ichinose, M ;
Takahashi, Y ;
Kume, H ;
Mimura, J ;
Fujii-Kuriyama, Y ;
Ishikawa, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) :779-782
[27]  
SMITH PF, 1989, IN VITRO TOXICOL, P93
[28]  
Stefaniak MS, 1992, IN VITRO TOXICOL, V5, P7
[29]  
THYSSEN J, 1981, J NATL CANCER I, V66, P575
[30]  
US Department of Health and Human Services, 1989, REP SURG GEN